PLX PROTALIX BIOTHERAPEUTICS INC Management Changes 8-K Filing 2025 - Resignations On April 21, 2025, Eyal Rubin, CFO of Protalix BioTherapeutics, announced his resignation effective in six months to pursue other opportunities, during which he will continue with his current role and receive full salary and benefits. He will also receive a severance payment and accelerated vesting of equity incentives upon departure.Get access to all SEC 8-K filings of the PROTALIX BIOTHERAPEUTICS INC